Rekindletech Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-12-2024
- Paid Up Capital ₹ 1.00 M
as on 17-12-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.50 M
as on 17-12-2024
About Rekindletech Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹4.50 M.
Rajesh Upadhyay, Siddharth Singh, and Kuldeep Upadhyay serve as directors at the Company.
- CIN/LLPIN
U24297GJ2020PTC114639
- Company No.
114639
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jul 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Rekindletech Pharmaceuticals Private Limited offer?
Rekindletech Pharmaceuticals Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Pain Reliever Gel, Nutraceuticals & Dietary Supplements, Fitness Supplements, Common Disease Medicines, Pharmaceutical Capsules.
Who are the key members and board of directors at Rekindletech Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kuldeep Upadhyay  | Director | 15-Jul-2020 | Current |
| Rajesh Upadhyay | Director | 16-May-2024 | Current |
| Siddharth Singh | Director | 27-Apr-2022 | Current |
Financial Performance of Rekindletech Pharmaceuticals.
Rekindletech Pharmaceuticals Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Rekindletech Pharmaceuticals?
In 2021, Rekindletech Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 Oct 2022 | ₹4.50 M | Open |
How Many Employees Work at Rekindletech Pharmaceuticals?
Rekindletech Pharmaceuticals has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rekindletech Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rekindletech Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
